These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 35144055)

  • 1. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.
    Villacampa G; Tolosa P; Salvador F; Sánchez-Bayona R; Villanueva L; Dienstmann R; Ciruelos E; Pascual T
    Cancer Treat Rev; 2022 Mar; 104():102352. PubMed ID: 35144055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
    BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.
    Villacampa G; Navarro V; Matikas A; Ribeiro JM; Schettini F; Tolosa P; Martínez-Sáez O; Sánchez-Bayona R; Ferrero-Cafiero JM; Salvador F; Papakonstantinou A; Prat A; Oliveira M; Pascual T
    JAMA Oncol; 2024 Oct; 10(10):1331-1341. PubMed ID: 39207778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis.
    Yang J; Liu C; Guo Y; Guo W; Wu X
    Front Oncol; 2024; 14():1309677. PubMed ID: 38406799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow.
    Li Y; Liang X; Li H; Chen X
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
    Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
    Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Brito ABC; Camandaroba MPG; de Lima VCC
    Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
    Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
    Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Li Y; Xing L; Li F; Liu H; Gan L; Yang D; Wang M; Yin X; Li H; Ren G
    Front Oncol; 2021; 11():657634. PubMed ID: 34912699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: A systematic review and meta-analysis.
    Gao X; Zhu Y; Wang P; Yu L; Ruan S; Shen M; Zhang K
    Cancer Med; 2023 Dec; 12(24):21873-21884. PubMed ID: 38063264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.
    Wang Y; Sun Y; Lu F; Zhao X; Nie Z; Zhu F; He B
    Clin Transl Oncol; 2024 Jul; 26(7):1725-1737. PubMed ID: 38587602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
    Qi Y; Yan X; Wang C; Cao H; Liu G
    Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
    [No Abstract]   [Full Text] [Related]  

  • 18. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Cui W; Luo Q; Sun SL; Xu JL; Gu H
    Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.